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A B S T R A C T
Background
There remains uncertainty about the optimum timing of antiretroviral therapy (ART) initiation in HIV-positive people with cryp-
tococcal meningitis. This uncertainty is the result of conflicting data on the mortality risk and occurrence of immune reconstitution
inflammatory syndrome (IRIS) when ART is initiated less than four weeks after cryptococcal meningitis treatment is commenced.
Objectives
To compare the outcomes of early initiation of ART (less than four weeks after starting antifungal treatment) versus delayed initiation
of ART (four weeks or more after starting antifungal treatment) in HIV-positive people with concurrent cryptococcal meningitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase for trials published between
1 January 1980 and 7 August 2017. We additionally searched international trial registries, including ClinicalTrials.gov and WHO
International Clinical Trials Registry Platform (ICTRP), and conference abstracts from the International AIDS Society (IAS) and the
Conference on Retroviruses and Opportunistic Infections (CROI) for ongoing or unpublished studies between 2015 and 2017. We
reviewed reference lists of included studies to identify additional studies.
Selection criteria
We included randomized controlled trials (RCTs) that compared early versus delayed ART initiation in HIV-positive people with
cryptococcal meningitis. Children, adults, and adolescents from any setting were eligible for inclusion.
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Data collection and analysis
Two review authors independently applied the inclusion criteria and extracted data. We presented dichotomous outcomes as risk ratios
(RR) with 95% confidence intervals (CIs). We presented time-to-death data as hazard ratios with 95% CIs. We assessed the certainty
of the evidence using the GRADE approach.
Main results
Four trials including 294 adult participants met the inclusion criteria of this review. Participants were predominantly from low- and
middle-income countries. Two trials treated cryptococcal meningitis with amphotericin B and fluconazole; a third trial used fluconazole
monotherapy; and the fourth trial did not specify the antifungal used.
Early ART initiation may increase all-cause mortality compared to delayed ART initiation (RR 1.42, 95% CI 1.02 to 1.97; 294
participants, 4 trials; low-certainty evidence). Early ART initiation may reduce relapse of cryptococcal meningitis compared to delayed
ART initiation (RR 0.27, 95% CI 0.07 to 1.04; 205 participants, 2 trials, low-certainty evidence). We are uncertain whether early ART
initiation increases or reduces cryptococcal IRIS events compared to delayed ART initiation (RR 3.56, 95% CI 0.51 to 25.02; 205
participants, 2 trials; I2 = 54%; very low-certainty evidence). We are uncertain if early ART initiation increases or reduces virological
suppression at six months compared to delayed ART initiation (RR 0.93, 95% CI 0.72 to 1.22; 205 participants, 2 trials; I2 statistic =
0%; very low-certainty evidence).
We were unable to pool results related to rate of fungal clearance for the two trials that reported this outcome; individual trial results
indicated that there was no difference in cerebrospinal fluid fungal clearance between trial arms. Similarly, we were unable to pool
results on adverse events for the trials reporting on this outcome; individual trial results indicated no difference in the occurrence of
grade 3 to 5 adverse events between trial arms.
Three of the four included trials had an overall low or unclear risk of bias related to the primary outcome of all-cause mortality. However,
we assessed one trial as at high risk of bias due to selective outcome reporting and other bias. This, in addition to the few clinical events
and imprecision of effect estimates, led to downgrading of the evidence to low or very low certainty.
Authors’ conclusions
The results of this review are relevant to HIV-positive adults with cryptococcal meningitis in low- and middle-income countries. These
data suggest a higher risk of mortality among people who initiate ARTwithin four weeks of cryptococcal meningitis diagnosis. However,
it is unclear if this higher mortality risk is related to cryptococcal meningitis-IRIS.
P L A I N L A N G U A G E S U M M A R Y
Timing of antiretroviral therapy initiation in HIV-positive people with cryptococcal meningitis
What is the aim of this review?
The aim of this Cochrane Review was to determine whether initiating antiretroviral therapy (ART) within four weeks of cryptococcal
meningitis diagnosis resulted in a higher risk of dying or developing other complications than waiting more than four weeks to initiate
ART.
Key messages
Initiating ART within four weeks of cryptococcal meningitis diagnosis may result in more deaths than initiating ART after four weeks.
However, initiating ART early may result in a reduction in relapses of cryptococcal meningitis after adequate treatment. There was
insufficient evidence to answer questions related to other complications.
What was studied in the review?
Cryptococcal meningitis is a fungal infection of the brain and the membranes covering the brain that occurs most frequently in people
with weakened immune systems, such as people who are HIV-positive. Some studies have shown that HIV-positive people who start
ART soon after initiating cryptococcal meningitis treatment (within four weeks) may deteriorate and die more frequently than those
who delay treatment for a longer period (more than four weeks). This higher risk of death in the early ART group has been attributed
to the occurrence of a condition called immune reconstitution inflammatory syndrome (IRIS). When ART is initiated, HIV-positive
people with underlying infections such as cryptococcal meningitis may paradoxically develop a deterioration in their condition as their
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body’s immune system attacks the fungus, resulting in worsening symptoms and sometimes death. It has been proposed that IRIS is
the cause of more deaths in early ART initiators than in delayed ART initiators. Despite adequate treatment of cryptococcal meningitis
with antifungal drugs, a relapse of the disease may occur in some HIV-positive people with cryptococcal meningitis. To date there have
been few trials investigating the effect of ART on mortality, frequency of IRIS, or relapse.
What are the main results of the review?
We found four relevant trials that compared HIV-positive adults who had cryptococcal meningitis and who initiated ART within four
weeks of cryptococcal meningitis diagnosis with those who initiated ART after four weeks.
Pooling the results of these four trials suggested that early ART initiation may increase the frequency of death in HIV-positive people
with cryptococcal meningitis (low-certainty evidence). Early ART initiators may be less likely to have relapses of cryptococcal meningitis
(low-certainty evidence). We were unable to draw conclusions regarding IRIS frequency as the certainty of the evidence contributing to
the IRIS assessment was very low. We are uncertain as to whether or not early ART initiation increases or reduces virological suppression
at six months compared to delayed ART initiation (very low-certainty evidence).
Overall, few trials met the inclusion criteria for this review, which made it hard to draw definite conclusions on the association between
ART timing and cryptococcal meningitis in HIV-positive people.
How up to date is the review?
We searched for studies up to 7 August 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Early ART compared to delayed ART initiation in HIV-positive people with cryptococcal meningitis
Patient or population: HIV-posit ive people with cryptococcal meningit is
Setting: global
Intervention: early ART init iat ion (less than 4 weeks af ter init iat ion of cryptococcal meningit is treatment)
Comparison: delayed ART init iat ion (more than 4 weeks af ter init iat ion of cryptococcal meningit is treatment)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with delayed ART Risk with early ART
All-cause mortality at 6
to 12 months
311 per 1000 442 per 1000
(317 to 613)
RR 1.42
(1.02 to 1.97)
294
(4 RCTs)
⊕⊕©©
LOW1,2,3
Early ART init iat ion may
increase the risk of
mortality at 6 to 12
months
Cryptococcal meningi-
t is relapse
87 per 1000 24 per 1000
(6 to 91)
RR 0.27
(0.07 to 1.04)
205
(2 RCTs)
⊕⊕©©
LOW4
Early ART init iat ion
may reduce relapses
of cryptococcal menin-
git is compared to de-
layed ART init iat ion
Cryptococcal IRIS 87 per 1000 311 per 1000
(45 to 1000)
RR 3.56
(0.51 to 25.02)
205
(2 RCTs)
⊕©©©
VERY LOW4,5,6
We are uncertain as to
whether or not early
ART init iat ion increases
or reduces cryptococ-
cal IRIS events com-
pared to delayed ART
init iat ion
HIV virological sup-
pression at 6 months
(viral load <400 copies/
mL)
534 per 1000 497 per 1000
(384 to 651)
RR 0.93 (0.72 to 1.22) 205
(2 RCTs)
⊕©©©
VERY LOW7,8
We are uncertain as to
whether or not early
ART init iat ion increases
or reduces virologi-
cal suppression at 6
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months compared to
delayed ART init iat ion
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: ART: ant iretroviral therapy; CI: conf idence interval; IRIS: immune reconst itut ion inf lammatory syndrome; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Risk of bias: downgraded by a half point due to high risk of other bias in Makadzange 2010.
2Imprecision: downgraded by 1 for wide CIs including no ef fect and appreciable harm. In addit ion, there were few clinical
events (< 200).
3Heterogeneity: downgraded by a half point due to qualitat ive heterogeneity (dif f erent drug regimens and study methods).
4Imprecision: downgraded by 2 for wide CIs and very few clinical events.
5Risk of bias: downgraded by 1 as IRIS outcome assessors in Bisson 2013 were unblinded.
6Indirectness: downgraded 1 as despite case def init ion, diagnosing IRIS can be very subject ive/ m isdiagnosed.
7Risk of bias: downgraded by 2 as not all those who were randomized to early or delayed ART received ART. In addit ion, not
all those who received ART had a viral load done. It cannot be assumed that these results are missing at random. This is
explored in the sensit ivity analyses.
8Imprecision: downgraded by 1 for few clinical events (< 200).
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B A C K G R O U N D
HIV/AIDS remains one of the world’s most significant public
health challenges, particularly in low- and middle-income coun-
tries. Antiretroviral therapy (ART) has substantially improved
HIV prognosis by reducing associated morbidity and mortality.
However uncertainty remains as to the optimal time for ART ini-
tiation when an HIV-positive person is co-infected with an op-
portunistic infection, particularly cryptococcal meningitis.
Description of the condition
Cryptococcal meningitis is an important opportunistic AIDS-
defining infection and a major contributor to high mortality be-
fore and after ART is initiated (Bicanic 2005; WHO 2013). It is
caused by the encapsulated yeast Cryptococcus neoformans, which
is inhaled as small yeast cells. Patients may present with headache,
fever,malaise, and alteredmental status; theymay also have signs of
meningism, papilloedema, and focal neurological deficits. Raised
intracranial pressure likely results from poor absorption of cere-
brospinal fluid (CSF); this is usually responsible for the central
nervous system manifestations. In addition to clinical history and
physical examination, laboratory investigations assist accurate and
timely diagnosis; recommended laboratory investigations include
cryptococcal antigen (CrAg) in CSF or serum, India Ink mi-
croscopy of CSF, or culture (Bicanic 2005; WHO 2013).
The case fatality rate in people with cryptococcal meningitis, the
most common presentation of HIV-related cryptococcal disease
in adults, remains unacceptably high, particularly in sub-Saharan
Africa, where it is between 35% to 65% compared with 10% to
20% in most high-income countries (Bicanic 2005; Park 2009;
WHO2016). In people who are immunocompromised, untreated
cryptococcal meningitis will uniformly lead to death in a few
weeks (Mwaba 2001). Cryptococcal meningitis is a leading cause
of death in HIV-positive people and typically affects those with
low cluster of differentiation 4 (CD4) counts (Rajasingham 2017;
Williamson 2017). Amphotericin B, flucytosine, and the azoles are
the mainstay antifungal treatments for cryptococcal meningitis.
Drug toxicity related to amphotericin B has been reported in up
to 60% of patients (Bicanic 2015; Meiring 2016). Cryptococcal
meningitis is less frequently described in children, although cases
do occur (NIH 2017b; Tinashe 2016). The best time to initiate
ART in those recently diagnosed with cryptococcal meningitis re-
mains an area of debate.
Description of the intervention
The treatment of cryptococcal meningitis is usually initiated with
a combination of antifungal agents (induction phase) followed by
a single oral antifungal (consolidation phase) (NIH 2017a; NIH
2017b; WHO 2018). The preferred induction regimen is ampho-
tericin B combined with flucytosine, followed by oral flucona-
zole for the consolidation phase, and until immune reconstitution
on ART. Current guidelines recommend initiating ART within
four to six weeks after cryptococcal meningitis treatment has com-
menced (WHO 2018).
How the intervention might work
There remains uncertainty as to when ART should be initiated in
people with cryptococcal meningitis. This is related to reports of
higher mortality rates among patients who initiate ART early in
cryptococcal meningitis treatment (Njei 2013). Immune recon-
stitution inflammatory syndrome (IRIS), an exaggerated inflam-
matory response that can cause a paradoxical clinical deterioration
soon after ART initiation, has frequently been described in associa-
tion with cryptococcal meningitis. Some reports suggest that IRIS
may contribute to higher mortality among HIV-positive people
who initiate ART early after a cryptococcal meningitis diagnosis
as compared to starting later, however there is no clear evidence of
such an association (Bicanic 2009;Müller 2010; Shelburne 2005).
Additionally, in many settings where cryptococcal meningitis is
prevalent, amphotericin B and flucytosine are unavailable due to
resource constraints. In such settings the use of suboptimal cryp-
tococcal meningitis treatment regimens with inadequate fungal
clearance may put patients at increased risk of developing relapses
and IRIS (Bicanic 2006; Loyse 2013).
Immune reconstitution inflammatory syndrome related to cryp-
tococcal disease has been defined as events occurring within 12
months of ART initiation, reintroduction, or regimen switching
after previous failure manifesting clinically as worsening disease
with one or more inflammatory manifestations of cryptococcosis
(meningitis, lymphadenopathy, intracranial space-occupying le-
sion or lesions, multifocal disease, cutaneous or soft-tissue lesions,
pneumonitis, or pulmonary nodules) (Haddow 2010).
Although many recommendations support delaying ART initia-
tion in people with cryptococcal meningitis (NIH 2017a; WHO
2018), delaying ART for long periods may increase the risk
of death or the development of other opportunistic infections
(Lundgern 2015).
Why it is important to do this review
Studies that have evaluated the impact of timing of ART initiation
in cryptococcal meningitis on mortality have, to date, had mixed
results. Most cohort studies have shown no association between
ART timing and mortality (Crabtree Ramírez 2017; Ingle 2015;
Manosuthi 2008). However, these cohort studies were underpow-
ered and limited by the inherent methodological issues with the
cohort study design (Table 1). A previous Cochrane Review sug-
gested that there was insufficient evidence in support of either
early or delayed initiation of ART (Njei 2013).
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Determining when ART should be initiated after a diagnosis of
cryptococcal meningitis involves balancing the survival benefit
conferred by ARTagainst the risk of IRIS. Conflicting data regard-
ing the relationship between the timing of ART for cryptococcal
meningitis and the high mortality pose a therapeutic dilemma,
and studies to date have had variable results.We aimed to incorpo-
rate recent randomized controlled trials and to update the findings
from the earlier review by Njei 2013.
O B J E C T I V E S
To compare the outcomes of early initiation ART (less than four
weeks after starting antifungal treatment) versus delayed initiation
of ART (four weeks or more after starting antifungal treatment)
in HIV-positive people with concurrent cryptococcal meningitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
HIV-positive children, adolescents, and adults with cryptococcal
meningitis.
Types of interventions
Early initiation of ART (ART initiated within four weeks of start-
ing antifungal treatment) versus delayed initiation of ART (ART
initiated at least four weeks after starting antifungal treatment).
Types of outcome measures
Primary outcomes
• All-cause mortality
Secondary outcomes
• Cryptococcal meningitis relapse
◦ Recurrence of cryptococcal meningitis symptoms in
previously laboratory-confirmed episode of cryptococcal
meningitis, with resolution of symptoms for one month after
treatment with participants being adherent to antifungal therapy,
and now presenting with CSF antigen test or culture positive for
C neoformans.
• CSF fungal clearance
• Mortality hazard ratio (HR)
• Paradoxical cryptococcal IRIS
◦ Fulfilling the Haddow 2010 case definition
• HIV virological suppression at six months
• Length of hospital stay
• Adverse events
◦ Clinical adverse events
◦ Laboratory adverse events
◦ Other adverse events
Search methods for identification of studies
We identified all relevant trials regardless of language or publica-
tion status.
Electronic searches
We searched the following databases:
Routine databases
• Cochrane Central Register of Controlled Trials
(CENTRAL): Issue 7 of 12, July 2017, search date 7 August
2017
• MEDLINE; search date 7 August 2017 (Appendix 1)
• Embase; search date 7 August 2017 (Appendix 2)
International trial registries
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov), searched on 7 August
2017
• WHO International Clinical Trials Registry Platform (
ICTRP) ( apps.who.int/trialsearch), searched on 7 August 2017
Searching other resources
Conference proceedings
• International AIDS Society ( IAS) conference abstracts (
2015 to 2017) ( www.iasociety.org)
• Conference on Retroviruses and Opportunistic Infections (
CROI) ( 2015 to 2017) ( www.croiconference.org/)
Other sources
We checked the reference lists of existing reviews and all trials
identified for other potentially relevant trials.
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Data collection and analysis
We conducted data collection and analysis following methods rec-
ommended in the Cochrane Handbook for Systematic Reviews of
Interventions and the Methodological Expectations for the Con-
duct of Cochrane Intervention Reviews (MECIR) (Higgins 2011;
Higgins 2016).
Selection of studies
Two review authors (MPO and IEW) independently screened the
titles and abstracts of all citations identified by searches against
our inclusion criteria based on types of studies, interventions, par-
ticipants, and outcomes. Both review authors evaluated the full-
text articles for inclusion. Where there was uncertainty about the
inclusion of a trial, we consulted a third review author (TB).
Data extraction and management
We piloted and then finalized a data extraction tool. Two review
authors (MPO and IEW) independently completed data extrac-
tion for the included trials and discussed discrepancies. In case of
disagreement, we consulted a third review author (TB).
For dichotomous outcomes, we extracted the number of partici-
pants who experienced the event and the number of participants
randomized to each treatment group. For time-to-event outcomes,
we extracted HRs and confidence intervals (CIs).
Assessment of risk of bias in included studies
Two review authors (MPO and IEW) independently assessed the
risk of bias for each trial using the Cochrane ‘Risk of bias’ assess-
ment tool (Higgins 2011). We contacted trial authors for missing
information or clarification, but did not receive any responses to
these queries. Two review authors independently applied the ‘Risk
of bias’ criteria to each trial, resolving any differences in opinion
through discussion or by consulting a third review author (MR).
We assessed the risk of bias across six domains: sequence genera-
tion, allocation concealment, blinding, incomplete outcome data,
selective outcome reporting, and other potential biases (Higgins
2011). For each domain, we assigned a judgement of either low,
high, or unclear risk of bias.
Measures of treatment effect
We presented dichotomous data using risk ratios (RR) with 95%
CIs. We used intention-to-treat analyses for all dichotomous data.
We presented time-to-event data using HRs with CIs.
Unit of analysis issues
No cluster-RCTs or trials with more than one intervention arm
met the inclusion criteria of this review.
Dealing with missing data
Where a trial publication provided insufficient data, we contacted
the trial authors to request the additional data (Bisson 2013;
Makadzange 2010). For analyses with persistent missing data, we
used available-case analysis and examined the robustness of this
approach by examining best- and worse-case scenarios. Bisson
2013 provided an HR with 95% CI that was not available in the
published manuscript; the method the authors used to generate
this HR is uncertain.
Assessment of heterogeneity
We assessed the degree of heterogeneity by a visual inspection of
forest plots and by examining the Chi2 test.
We quantified the extent of heterogeneity by calculating an esti-
mation of the I2 statistic. We followed the guidance outlined in
Section 9.5.2 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity
Where heterogeneity was present in pooled effect estimates, we
explored possible reasons for variability by conducting subgroup
analyses. Due to the limited number of trials and participants
contributing to each outcome, we were restricted in the number
of subgroup analyses we could conduct.
Assessment of reporting biases
We assessed publication bias qualitatively based on the character-
istics of the included trials. There were insufficient trials to con-
struct a funnel plot.
Data synthesis
We performed analyses using Review Manager 5 (RevMan 2014).
When trials were considered clinically and methodologically
comparable, we conducted meta-analyses using a random-effects
model. We presented narrative results of outcomes only if there
was insufficient data for a meta-analysis. For time-to-event data,
we used HRs and CIs to generate log HRs and standard errors and
used the generic inverse-variance method to analyse these data.
Certainty of the evidence
We assessed the certainty of the evidence for each outcome using
the GRADE approach (Guyatt 2008), which defines the certainty
of the evidence for each outcome as “the extent to which one can
be confident that an estimate of effect or association is close to the
quantity of specific interest” (Higgins 2011). The GRADE cer-
tainty rating has four levels: high, moderate, low, or very low. We
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initially categorized RCTs as high-certainty evidence, and down-
graded the certainty of the evidence after assessment of five criteria:
risk of bias, consistency, directness, imprecision, and publication
bias (Guyatt 2011). Two review authors (IEW and MPO) inde-
pendently performed this assessment, resolving any disagreements
by discussion.
We constructed ‘Summary of findings’ tables and GRADE evi-
dence tables to present the results of primary and secondary out-
comes. We used GRADEpro GDT software to generate the ‘Sum-
mary of findings’ tables (GRADEpro GDT 2015).
Subgroup analysis and investigation of heterogeneity
We had initially intended to conduct subgroup analyses for the
primary outcome to investigate heterogeneity produced by anti-
fungal drug treatment, geographical region, Glasgow coma score
at randomization, and CSF white blood cell count. Due to limited
data, we only conducted a subgroup analysis by antifungal drug
treatment.
Sensitivity analysis
We used sensitivity analyses to assess the robustness of results.
Where data were missing, we assessed best- and worst-case scenar-
ios to determine the possible impact of missing data on the overall
effect estimates. For the cryptococcal IRIS outcome, those partici-
pants who died in the early ART and delayed ART groups may not
have been missing completely at random, therefore the assump-
tion in themain analysis (available-case analysis) may be flawed. In
addition, using an intention-to-treat analysis would suggest that
all those who died would not have developed IRIS. We therefore
conducted sensitivity analyses to determine the influence of dif-
ferent risks for IRIS among those who died before they could have
received ART or developed IRIS. To evaluate this, we applied a
best-case scenario (8% of those who died in the early ART group
would have developed IRIS and 46% of those who died in the
delayed ART group would have developed IRIS) and a worst-case
scenario (46% of those who died in the early ART group would
have developed IRIS and 8% of those who died in the delayed
ART group would have developed IRIS). This was based on the
range of reported incidence (8% to 46%) of paradoxical crypto-
coccal IRIS (Haddow 2010).
Viral load results were only available for a subset of participants
in the two trials that reported on this outcome. For our current
analysis we assumed these participants to be missing completely at
random, however it is possible that participants who died before
they received ART or who did not have viral load measurements
done despite receiving ART differed from those who had results.
We applied best- and worst-case scenarios to these estimates to
examine our results. These estimates were based on the range of
viral load suppression rates (50% to 89%) reported by JointUnited
Nations Programme on HIV/AIDS (UNAIDS) for Eastern and
sub-Saharan Africa (UNAIDS 2017).
R E S U L T S
Description of studies
Four trials met the inclusion criteria for this review (Bisson 2013;
Boulware 2014;Makadzange 2010;Zolopa 2009). SeeTable 2, the
‘Characteristics of included studies’ tables, and the ‘Characteristics
of excluded studies’ tables for trial details.
Results of the search
We searched for trials published between 1 January 1980 and 7
August 2017. The search results are presented in a PRISMA flow
diagram (Figure 1). The electronic searches identified 314 titles
and abstracts (80 from clinical trial registries, 180 from routine
databases, and 54 from conference abstracts). After de-duplica-
tion, 273 records underwent title and abstract screening. We iden-
tified 13 records for full-text eligibility screening. We excluded
seven of these records with reasons (two further duplicates, two
journal correspondence, three wrong study design). We included
six records representing four trials in the qualitative and quantita-
tive synthesis.
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Figure 1. Study flow diagram.
Included studies
We have provided a summary of the included trials in Table 2 and
further individual trial details in the ‘Characteristics of included
studies’ tables.
Participants
The Zolopa 2009 trial included participants with several different
types of opportunistic infections and did not disaggregate infor-
mation for those with cryptococcal meningitis, therefore limited
descriptive data could be provided for this trial.
Setting
We included four trials with 294 participants from Botswana,
Puerto Rico, South Africa, Uganda, the USA, and Zimbabwe.
Trials were conducted between May 2003 and November 2011.
Demographic characteristics
We did not identify any studies conducted in children less than
13 years old. Most trials included only adults aged more than 18
or 21 years, except Zolopa 2009, which also included adolescents
aged 13 years and over. Approximately 50% of participants were
male in Boulware 2014, Bisson 2013, andMakadzange 2010. The
median or mean age ranged from 35 to 38 years.
HIV illness
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All trials included participants who were HIV-positive and had a
diagnosis of cryptococcal meningitis or other opportunistic infec-
tion (Zolopa 2009).
Exclusion criteria
Previous or current ART use was an exclusion criterion for all
trials. All trials except Zolopa 2009 further excluded pregnancy/
lactation and concurrent central nervous system infections such as
bacterial meningitis.
Intervention and comparison
Antifungal therapy
Antifungal treatment regimens differed markedly between tri-
als. Two trials used a combination of amphotericin B and flu-
conazole in the induction and consolidation antifungal regimen
(Bisson 2013; Boulware 2014); one trial used fluconazole only
(Makadzange 2010); and one trial did not report on the antifungal
regimen (Zolopa 2009). Bisson 2013 provided amphotericin B
(0.7 mg/kg/day) for two weeks, followed by oral fluconazole 400
mg daily for eight weeks. Boulware 2014 administered two weeks
of amphotericin B (0.7 to 1.0mg/kg/day) combined with flucona-
zole (800 mg/day) followed by 800 mg of fluconazole per day for
at least three weeks or until a CSF culture was sterile, followed by
400 mg of fluconazole per day thereafter, for a total consolidation
period of at least 12 weeks. Makadzange 2010 used fluconazole
800 mg daily for 10 weeks. These three trials also reported pre-
scribing secondary prophylaxis of 200 mg of fluconazole per day
after the induction and consolidation phases of antifungal treat-
ment.
Boulware 2014 reported that participants received between 7 and
11 days of antifungal therapy prior to randomization, and Zolopa
2009 also allowed for ≤ 14 days of antifungal treatment prior
to randomization for ART initiation. Bisson 2013 randomized
participants within 72 hours of antifungal therapy initiation, and
Makadzange 2010 randomized participants at the time of cryp-
tococcal meningitis diagnosis. Only one trial described providing
supportive care in the form of electrolyte replacement, fluid man-
agement, and routine therapeutic lumbar punctures (Boulware
2014).
Antiretroviral therapy
Three trials reported using a combination of two nucleoside re-
verse transcriptase inhibitors including tenofovir, emtricitabine,
zidovudine, and stavudine, and one non-nucleoside reverse tran-
scriptase inhibitor, either efavirenz or nevirapine (Bisson 2013;
Boulware 2014;Makadzange 2010), or protease inhibitor (Zolopa
2009).
Early ART
For early initiation of ART, all trials reported starting ART
within two weeks of randomization (Bisson 2013; Boulware 2014;
Makadzange 2010), with one trial initiating ART within 5 to 10
days (Bisson 2013), another within 1 to 2 weeks (Boulware 2014),
and two trials initiating ART within 72 and 48 hours, respectively
(Makadzange 2010; Zolopa 2009).
Delayed ART
Two trials reported initiating delayed ART around the one-month
mark: Boulware 2014 (five weeks) and Bisson 2013 (32 days).
Makadzange 2010 initiated delayed ART at a median of 10 weeks,
and the delayed group in Zolopa 2009 initiated ART between 6
and 12 weeks after randomization.
Outcomes
Three trials reported on all-cause mortality at 6 to 12 months af-
ter randomization; we obtained additional data for this outcome
directly from the authors of Makadzange 2010. Zolopa 2009 re-
ported 12-month mortality, while the remaining trials reported
six-month mortality.
Only Bisson 2013 and Boulware 2014 reported cryptococcal
meningitis relapse, CSF fungal clearance, cryptococcal IRIS, and
HIV virological suppression at six months. Cerebrospinal fluid
fungal clearance was reported by treatment arm as the rate of fun-
gal clearance by Bisson 2013 and as the cumulative incidence of
CSF culture positivity at 14 days of amphotericin B therapy by
Boulware 2014.
Three trials presented mortality time-to-event data (Bisson 2013;
Boulware 2014; Makadzange 2010). Makadzange 2010 and
Boulware 2014 reported unadjusted HRs, while Bisson 2013 pre-
sented a Kaplan Meier survival curve from which the HR was de-
rived (see Dealing with missing data).
No trials reported length of hospital stay as a trial outcome; Bisson
2013 reported only on prolonged hospitalizations, however this
was not defined.
Varying details on adverse events were present for all trials ex-
cept Zolopa 2009. Bisson 2013 described at least one grade 3
to 5 Division of AIDS (DAIDS) adverse event, and Boulware
2014 described the cumulative incidence of such events, while
Makadzange 2010 gave limited narrative information on adverse
events.
Excluded studies
We excluded seven publications after full-text assessment for the
reasons described in the ‘Characteristics of excluded studies’ tables
(Makadzange 2015a; Makadzange 2015b; Makadzange 2015c;
Manosuthi 2008; Sungkanuparph 2009; Sunpath 2012; Torok
2005).
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Risk of bias in included studies
We evaluated the risk of bias of included trials for each of the
six domains (see the ‘Characteristics of included studies’ tables).
We did a graphical summary of the ‘Risk of bias’ assessment as
represented in Figure 2 and Figure 3 .
Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each ‘Risk of bias’ item for each
included trial.
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Figure 3. ‘Risk of bias’ graph: review authors’ judgements about each ‘Risk of bias’ item presented as
percentages across all included trials.
Allocation
Three of the four included trials adequately described random
sequence generation and allocation concealment and were con-
sidered free of selection bias (Boulware 2014; Makadzange 2010;
Zolopa 2009). One trial had an unclear risk of selection bias for
both random sequence generation and allocation concealment,
which were inadequately described (Bisson 2013).
Blinding
All four trials were open-label trials, that is participants and per-
sonnel were not blinded to treatment allocation group; we assessed
these trials as having a high risk for performance bias. Outcome
assessors were generally not blinded in the included trials for most
outcomes. Two trials blinded IRIS outcome assessors (Boulware
2014; Zolopa 2009). We did not consider blinding an issue for
mortality assessment and laboratory results, as these are objective
outcomes, however adverse events and IRIS are fairly subjective.
As a result, we assessed most trials as having an overall unclear risk
of bias for outcome assessment.
Incomplete outcome data
The proportion of participants lost to follow-up was low (< 15%)
in all trials. There was also no evidence of differential loss to follow-
up. Zolopa 2009 only reported attrition for the total number of
randomized participants and not specifically for those with crypto-
coccal meningitis; overall approximately 13% of participants were
lost follow-up in this trial. We assessed all trials as at low risk of
attrition bias.
Selective reporting
Two trials had published protocols that were available for assess-
ment (Bisson 2013; Boulware 2014); these trials reported all rel-
evant outcomes and were assessed as at low risk of reporting bias.
We classified two trials as at unclear risk of bias for selective out-
come reporting: Zolopa 2009 did not have a protocol available for
assessment, and the protocol for Makadzange 2010 was only pub-
lished after the trial was completed, and no prespecified outcomes
were included in the published protocol.
Other potential sources of bias
One trial was at high risk of other potential sources of bias
(Makadzange 2010). Some reported results were not arithmeti-
cally correct, which could have had an impact on effect estimates.
In addition, the authors were not consistent with the intention-to-
treat approach, which could have affected the time-to-event anal-
ysis. Concerns about the results of this trial are echoed in com-
ments from other trial authors in the same field, as referenced in
the Characteristics of included studies tables.
Effects of interventions
See: Summary of findings for the main comparison Early ART
compared to delayed ART initiation in HIV-positive people with
cryptococcal meningitis
Early (< 4 weeks) versus delayed (≥ 4 weeks) ART
initiation in HIV-positive people with cryptococcal
meningitis
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Four trials with 294 participants contributed data to this compar-
ison. See also Summary of findings for the main comparison for a
summary of the overall results.
Primary outcomes
All-cause mortality at six to 12 months
There was higher mortality at this time point for those receiving
early ART compared to those for whom ART was delayed (risk
ratio (RR) 1.42, 95% confidence interval (CI) 1.02 to 1.97; 294
participants, 4 trials; I2 = 13%; Analysis 1.1; Figure 4). The cer-
tainty of the evidence contributing to this outcome was low due
to concerns regarding risk of bias and qualitative heterogeneity in
the included trials and imprecision. We conducted a sensitivity
analysis including only trials at an overall low risk of bias (Analysis
1.2).
Figure 4. Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.1 All-cause mortality at 6 to 12
months.
Secondary outcomes
Cryptococcal meningitis relapse
There was a trend towards a reduction in cryptococcal meningitis
relapse with early ART compared to delayed ART. However, this
effect did not reach statistical significance, as the CI included no
effect (RR 0.27, 95% CI 0.07 to 1.04; 205 participants, 2 trials;
I2 = 0%; Analysis 1.3; Figure 5). The certainty of the evidence
contributing to this outcome was low due to imprecision (few
clinical events).
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Figure 5. Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.3 Cryptococcal meningitis
relapse.
Cerebrospinal fluid fungal clearance
Due to the variability in methods of reporting CSF fungal clear-
ance, we could not pool the results from the two trials that reported
on this outcome. We have presented these results narratively in
Table 3. Both trials found no difference in the rate of CSF fungal
clearance between the two trial arms.
Mortality hazard ratio
Due to considerable unexplainedheterogeneity in the pooled effect
estimate from the trials where hazard ratios were provided (237
participants, 3 trials; I2 = 84%; Analysis 1.4), we did not meta-
analyse this outcome.
Cryptococcal IRIS
There was a suggestion of an increased risk of cryptococcal IRIS
associated with early ART (RR 3.56, 95% CI 0.51 to 25.02; 205
participants, 2 trials; I2 = 54%; Analysis 1.5; Figure 6). However,
the CI around this estimate was very wide and included no effect.
The certainty of the evidence for this outcome was very low due to
marked imprecision of the estimate, risk of bias, and indirectness
related to the IRIS assessment. We explored the use of available-
case analysis for this outcome in a sensitivity analysis (Analysis 1.6,
Figure 7).
Figure 6. Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.5 Cryptococcal IRIS.
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Figure 7. Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.6 Sensitivity analysis:
cryptococcal IRIS.
HIV virological suppression
There was little to no difference in virological suppression at 24
weeks with early ART compared to delayed ART (RR 0.93, 95%
CI 0.72 to 1.22; 205 participants, 2 trials; I2 = 0%; Analysis 1.7).
The certainty of the evidence contributing to this outcome was
very low due to high risk of bias and imprecision (few clinical
events). We explored the use of available-case analysis for this out-
come in a sensitivity analysis (Analysis 1.8; Figure 8).
16Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 8. Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.8 Sensitivity analysis:
virological suppression at 24 weeks.
Length of hospital stay
No trials reported length of hospital stay as an outcome. Bisson
2013 reported only prolonged hospitalizations as 2 (15%) and 4
(29%) in early and delayed ART arms, respectively.
Adverse events
Adverse eventmeasureswere not reported consistently between tri-
als, therefore these data could not be meta-analysed. Bisson 2013
reported that all 14 participants in the early ART arm and 13/
14 participants in the delayed ART arm experienced at least one
grade 3 to 5 adverse event. Boulware 2014 reported the cumu-
lative incidence of grade 3 to 5 adverse events as 84% (95% CI
74% to 90%) in the early ART group and 84% (95% CI 75% to
91%) in the delayed ART group.Makadzange 2010 described one
episode of desquamating skin rash related to nevirapine and that
liver function tests remained normal throughout the trial. Zolopa
2009 did not report adverse events specifically for participants
with cryptococcal meningitis.
Subgroup analyses
All-cause mortality by antifungal therapy
We subgrouped the primary outcome of all-cause mortality ac-
cording to type of antifungal therapy used. Among trials where
amphotericin B therapy was combined with fluconazole (Bisson
2013; Boulware 2014), there was substantial unexplained hetero-
geneity between trials (I2 = 66%), and effect estimates were not
pooled. A further trial treated cryptococcal meningitis with flu-
conazole monotherapy (Makadzange 2010); the results of this trial
indicated that those who initiated ART early had higher mortal-
ity compared to those who initiated ART later (RR 1.57, 95%
CI 1.02 to 2.42; 54 participants; Analysis 1.9). Zolopa 2009 did
not specify which antifungal therapy was used (RR 0.85, 95% CI
0.08 to 8.44; 35 participants; Analysis 1.9) and showed no overall
difference in mortality between the treatment arms.
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Sensitivity analyses
All-cause mortality
We explored the effect of the intervention on all-cause mortality
at six months by restricting the analysis to trials with low risk of
bias for sequence generation, attrition, and other bias that could
influence this outcome.
Only the Cryptococcal Optimal ART Timing (COAT) trial,
Boulware 2014, contributed to this analysis. The results from this
trial indicated a higher risk of mortality among those who initiated
ART early compared to those who delayed ART (RR 1.50, 95%
CI 1.02 to 2.21; 177 participants, 1 trial; Analysis 1.2).
Cryptococcal IRIS
Applying an available-case analysis (RR 2.97, 95% CI 0.38 to
23.25; Analysis 1.6: Figure 7) and applying a low (8%) or high
(46%) occurrence of cryptococcal IRIS to the missing cases dif-
ferentially in the best-case (RR 1.56, 95% CI 0.45 to 5.40) and
worst-case scenarios (RR 3.73, 95% CI 0.37 to 38.07) only re-
sulted in a lower or higher precision estimate. In all instances, the
estimates included no effect, and CIs remained wide and included
appreciable benefit and harm. These results are in keeping with
the intention-to treat analysis suggesting that this approach was
reasonable for the analysis of cryptococcal IRIS.
Virological suppression on ART
We compared the use of an available-case analysis and best- and
worst-case scenarios to evaluate missing data for this outcome.
This resulted in a persistent result of no difference in virological
suppression at six months between groups in the available-case
analysis (RR 1.10, 95% CI 0.96 to 1.27; Analysis 1.8; Figure 8).
For the best-case scenario, we assumed 89% virological suppres-
sion for those missing viral loads or who did not receive ART in the
early ART group and 50% for those missing in the delayed ART
group. This resulted in better virological suppression in the early
ART group (RR 1.26, 95% CI 1.10 to 1.45). When we applied
the worst-case scenario and assumed that those missing viral loads
or who did not receive ART in the early ART group had 50%
suppression and in the delayed ART group had 89% suppression,
this resulted in better virological suppression in the delayed ART
group (RR 0.84, 95% CI 0.72 to 0.96). This suggested that the
missing data for virological outcomes could bias results for this
outcome and led to a downgrading of this outcome in theGRADE
assessment.
Certainty of the evidence
We used GRADE to indicate the level of confidence we have in
the results. The certainty of the evidence was either low or very
low for most outcomes.
Methodological quality
The overall methodological quality was unclear for most trials
that contributed to the analyses, due predominantly to the lack
of reporting on several ’Risk of bias’ domains. We categorized
Makadzange 2010 as at high risk of bias for three domains, and
the inclusion of this trial in the mortality analyses resulted in
downgrading for risk of bias for these outcomes. Due to the lack of
blinding of IRIS outcome assessors in one trial, we downgraded the
evidence that contributed to the IRIS analysis. Viral load analysis
was not conducted for all participants who were randomized or
who received ART; we downgraded the certainty of the evidence
for this outcome, as it is possible that randomization was not
maintained for the subgroup that was analysed for this outcome.
Consistency
Wedetected qualitative and quantitative heterogeneity in the anal-
ysis of mortality, which led to downgrading the certainty of the ev-
idence for the all-cause mortality outcome and prevented pooling
of the results of the mortality hazard ratio outcome. We explored
the use of different antifungal regimens in a subgroup analysis and
found substantial heterogeneity between the trials providing am-
photericin B, reflecting differences between these trials that could
not be explained. This inconsistency could be the result of differ-
ences in the trial setting and conduct, however it was not possible
to fully account for this in subgroup analyses.
Indirectness
We downgraded the cryptococcal IRIS outcome for indirectness,
as we considered IRIS assessment to be quite subjective even when
case definitions are applied.
Imprecision
Wedowngraded all outcomes due to imprecision. There were over-
all few clinical events contributing to each analysis. In addition,
several analyses had wide CIs including no effect and appreciable
harm or benefit.
Publication bias and other considerations
It was not possible to formally assess publication bias using funnel
plots. However, there was no evidence of publication bias among
the included trials, which presented both results with no effect or
moderate effects of early ART on mortality.
D I S C U S S I O N
Summary of main results
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Four trials including a total of 294 participants evaluated early
ART initiation compared to delayed ART initiation (Summary
of findings for the main comparison). The trials were conducted
between 2003 and 2011, and all included people from low- and
middle-income countries. Two trials used amphotericin B and
fluconazole for cryptococcal meningitis induction therapy; one
trial used fluconazole monotherapy; and one trial did not report
the induction therapy used. All trials were conducted in adults.
Primary outcomes
Overall, when we pooled results from the four included trials we
found that early ART initiation may increase all-cause mortality
at six to 12 months among HIV-positive adults with cryptococcal
meningitis, with low-certainty evidence contributing to this meta-
analysis. A sensitivity analysis restricted to trials at low risk of bias
showed higher risk of mortality among those initiating ART early;
this analysis included one high-quality trial (COAT trial), which
was terminated early due to the higher mortality risk in the early
ART group.
Secondary outcomes
There was low-certainty evidence suggesting that early ART ini-
tiation may reduce the occurrence of cryptococcal meningitis re-
lapse. Two RCTs evaluating the risk of developing IRIS found a
tendency towards increased risk of cryptococcal IRIS in the early
ART group, however the very low-certainty evidence contributing
to this outcome means that we cannot say whether early ART ini-
tiation increases or decreases cryptococcal IRIS events compared
to delayed ART initiation. We are uncertain if early ART affects
virological suppression at six months, as the evidence contributing
to this outcome was of very low certainty. Adverse events were
not reported consistently between trials, therefore could not meta-
analyse this outcome. Conclusions from the authors of trials that
assessed this outcome suggest no difference in grade 3 to 5 ad-
verse events between the two treatment arms. Similarly, data from
the two trials reporting on time to fungal clearance could not be
pooled, and the authors of these trials concluded that there was no
difference between early and delayed ART arms for this outcome.
Overall completeness and applicability of
evidence
We found only a few small trials that evaluated early versus delayed
ART initiation in HIV-positive people with cryptococcal menin-
gitis. The trials were generally conducted in low- and middle-in-
come countries and included only adult participants. The results
from this review can therefore be generalized only to these groups.
The overall low certainty of the evidence limits the conclusions
that can be drawn from these analyses. However, the pooled results
do suggest that early ART may increase all-cause mortality. We
were restricted in the number of subgroup and sensitivity analy-
ses that we could perform due to the limited number of included
trials and participants. When we restricted analyses to trials at low
risk of bias for the primary outcome, the analysis contained one
trial (Boulware 2014); these results showed a higher risk of mor-
tality among those who initiated ART early. In addition, two of
the included studies with the highest numbers of participants and
showing higher mortality with early ART were terminated early
due to excessive mortality in the early ART group. One needs to
consider whether effect estimates would be higher if these trials
had larger samples.
Only two trials reported using amphotericin B-based induction
therapy, which is the standard of care for treatment of people
with cryptococcal meningitis. Although fluconazole monotherapy
is not routinely recommended, in many low- and middle-income
countries this single agent may still be used, and so findings from
this trial remain relevant to these settings.
Immune reconstitution inflammatory syndrome has been impli-
cated as the reason for higher mortality in those who initiate ART
early. Unfortunately, we could draw no conclusions on the effect
of early ART on IRIS occurrence based on the available data.
Certainty of the evidence
Overall, the certainty of the evidence contributing to all out-
comes was low or very low. This was due to generally few clinical
events and wide CIs around effect estimates. In addition, the poor
methodological quality of some trials that contributed to the mor-
tality, cryptococcal meningitis IRIS, and virological suppression
analyses led to further downgrading of these outcomes.
Potential biases in the review process
Weminimized selection bias by conducting an extensive literature
search using awide range of search terms anddatabases. Two review
authors independently screened the search outputs and evaluated
eligibility. In addition, we evaluated the reference lists of included
papers and previous systematic reviews.
We have detailed any changes made to the trial protocol after
publication and after the review process began in the Differences
between protocol and review section.
Agreements and disagreements with other
studies or reviews
A previous Cochrane Review conducted by Njei 2013 included
two of the four trials included in this review (Makadzange 2010;
Zolopa 2009). They concluded that therewas insufficient evidence
to determine whether early ART had an effect on mortality and
suggested that there was a higher risk of IRIS among those who
initiated ART early. Although our review did show some evidence
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of higher risk of IRIS in the early ART group, the certainty of the
evidence contributing to this outcome was very low. The addi-
tional trials that contributed to this updated review, and rigorous
application of the GRADE tool, resulted in low-certainty evidence
of higher mortality among those who initiated ART early.
These findings contrast with cohort studies, which suggest no
difference in mortality risk when comparing early ART to delayed
ART (Table 1). This may reflect some level of selection bias for
this outcome in cohort studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite the low certainty of the evidence, it appears that initi-
ating antiretroviral therapy (ART) within four weeks of crypto-
coccal meningitis diagnosis increases the risk of mortality com-
pared to delaying ART beyond four weeks. Clinicians and guide-
line developers need to seriously consider the severe nature of the
potential harms of initiating ART early in HIV-positive people
with cryptococcal meningitis. Findings from this Cochrane Re-
view contributed to the formulation of the current World Health
Organization (WHO) guidelines for the diagnosis, prevention,
and management of cryptococcal disease in HIV-positive adults,
adolescents, and children (WHO 2018).
Implications for research
With this suggestion of a higher risk of mortality in HIV-posi-
tive people with cryptococcal meningitis who initiate ART early,
it is unlikely that more randomized controlled trials will be con-
ducted that evaluate early versus delayed ART as an intervention
in people with cryptococcal meningitis. Questions regarding how
to best manage patients who develop cryptococcal meningitis soon
after ART initiation were not addressed in this Cochrane Review
and will become more relevant as rapid ART initiation becomes
widespread.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bisson 2013
Methods Study design: open-label RCT
Participants Inclusion criteria: adults ≥ 21 years of age: HIV-positive, (positive enzyme-linked
immunosorbent assay and/or a detectable (i.e. > 400 copies/mL) plasma viral load)
; India ink-positive cryptococcal meningitis; ART-naive, no past use of ART besides
for prevention of mother-to-child transmission ≥ 6 months previously; could provide
written informed consent; to initiate or had initiated amphotericin B≤ 72 hours prior to
enrolment; no antifungal use within the prior 14 days; not pregnant, as determined by a
negative urineβ-human chorionic gonadotropin test, or were breastfeeding; not initiated
antitubercular therapy ≤ 2 weeks prior to assessment; not have bacterial meningitis;
unlikely to initiate immunomodulatory therapy (e.g. cancer chemotherapy) prior to the
week 4 study visit; not prisoners; available CSF for determination of baseline CFUs; and
would obtain outpatient care within the logistical reach of the study team. Informed
consent
Exclusion criteria: patients not meeting the inclusion criteria
Number randomized: 28
Descriptive baseline data:
• Age: median: 35 years (IQR 32 to 41)
• Sex: n = 14 (52%) male
• CD4 count: median: 29 (IQR 11 to 50) cells/µL
• Fungal burden: median: 5.7 log10 CFU (IQR 5.2 to 6.5)
• GCS: median: 15 (IQR not reported)
Duration of antifungal therapy prior to randomization: 72 hrs
Dropouts during study period: 1
Interventions Antifungal therapy provided: amphotericin B 0.7 mg/kg × 14 days, followed by oral
fluconazole 400 mg daily × 8 weeks, followed by oral fluconazole 200 mg daily until the
CD4 count is > 200 cells/µL for 6 months
Supportive care: not described
CSF pressure management: not described
ART regimen provided: 18 (82%) participants initiated combination TDF/FTC/EFV,
whereas the remaining 4 participants initiated combination zidovudine/lamivudine plus
NVP or EFV (2 participants) or TDF/FTC and NVP (2 participants)
Early ART: 12 of 13 (92%) participants initiated ART at a median of 7 days (IQR 5 to
10) after randomization
Delayed ART: 10 of 14 (71%) participants in the control arm initiated ART at a median
of 32 days (IQR 28 to 36) after randomization
Adherence: not reported
Outcomes Primary outcomes
• All-cause mortality
• Cryptococcal meningitis relapse
Secondary outcomes
• Time to CSF fungal clearance: “fungal colony forming units (CFUs) were
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Bisson 2013 (Continued)
measured using a standard protocol on the initial CSF sample submitted for diagnosis,
on CSF obtained at a study-specific lumbar puncture performed 4 weeks after
randomization, and on available CSF obtained from other lumbar punctures.”
• Time to death (authors provided additional unpublished data - HR for mortality)
• IRIS: defined by 2 research team physicians unblinded using Haddow 2010
definition
• Adverse events: incident adverse events were graded using the Division of AIDS
Table for Grading Adult Adverse and Pediatric Adverse Events
• Virological suppressions
Timing of outcome measurement
Study-specific visits, performed at entry and at days 7 and 14, week 4, and monthly
thereafter, included medical history and physical examination
HIV load, CD4 count, and complete blood count were performed at randomization, at
week 4, and then at weeks 12 and 24 after the planned date of ART initiation
Serum chemistries were performed as above and at days 7 and 14
Study-specific lumbar puncture performed 4 weeks after randomization
Notes Country: Botswana
Setting: hospital setting
Dates: September 2009 and November 2011
Funding: Doris Duke Charitable Foundation via a Doris Duke Clinical Scientist De-
velopment Award (to GPB) and by the Penn Center for AIDS Research International
Core
Other: early study termination due to slow recruitment and funding (planned sample
size = 25 per study arm)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors mention randomization, but do not
describe how this was done
Allocation concealment (selection bias) Unclear risk The trial authors do not describe the allocation con-
cealment process
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessment was not reported as blinded. Im-
mune reconstitution inflammatory syndrome assess-
ment was unblinded. This is unlikely to bias results
for mortality and laboratory tests, however bias could
be introduced for adverse events and IRIS
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant dropped out after randomization.
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Bisson 2013 (Continued)
Selective reporting (reporting bias) Low risk This trial was registered on ClinicalTrials.gov in 2009:
clinicaltrials.gov/ct2/archive/NCT00976040
clinicaltrials.gov/ct2/show/NCT00976040
2 proposed outcomes were not reported:
• Clearance of Cryptococcus neoformans antigen
from CSF and blood (time frame: 6 months)
• Change in the number of peripheral blood
mononuclear cells responding to C neoformans (time
frame: 4 weeks)
We do not see these as introducing bias, as all main
relevant outcomes were reported
Other bias Low risk We did not identify any other potential sources of bias.
Boulware 2014
Methods Study design: open-label RCT
Participants Inclusion criteria: 18 years or older, diagnosed with HIV infection, no previous receipt
of ART, a diagnosis of cryptococcalmeningitis based onCSF culture or CSF cryptococcal
antigen assay, and treatment with amphotericin-based therapy
Exclusion criteria: inability to undergo follow-up, contraindication for or refusal to un-
dergo lumbar punctures, multiple concurrent CNS infections, previous cryptococcosis,
receipt of chemotherapy or immunosuppressive agents, pregnancy, breastfeeding, and
serious coexisting conditions that precluded random assignment to earlier or deferred
ART
Number randomized: 177
Descriptive baseline data
• Age (median (IQR) years): early ART 32 (28 to 40); delayed ART 36 (30 to 40)
• Sex (% male): early ART 52%; delayed ART 53%
• CD4 count (median (IQR) cells/µL): early ART 19 (9 to 69); delayed ART 28
(11 to 76)
• Fungal burden (median (IQR) log10 CFU/mL): early ART 5.3 (4.2 to 5.7);
delayed ART 4.8 (3.8 to 5.5)
• GCS (% with GCS < 15): early ART 24% ; delayed ART 30%
Dropouts during study period: 1
Interventions Duration of antifungal therapy prior to randomization: 7 to 11 days
Antifungal therapy provided: induction therapy: 2 weeks amphotericin B (0.7 to 1.0
mg/kg/day) combined with fluconazole (800 mg/day)
Followed by 800 mg of fluconazole per day for at least 3 weeks or until a CSF culture was
sterile, followed by 400 mg of fluconazole per day thereafter, for a total consolidation
period of at least 12 weeks. Secondary prophylaxis with fluconazole (200 mg per day)
was then continued for at least 1 year
Supportive care: intravenous fluids (≥ 2 L per day) and electrolyte management
CSF pressure management: additional LPs were conducted on days 7 and 14, and for
control of intracranial pressure
ART regimen provided: AZT, 3TC, EFV (80%), D4t, 3TC, EFV (19%), TDF, 3TC,
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Boulware 2014 (Continued)
EFV (1%)
Early ART initiation: 86 (98%) received ART within 48 hrs. Median of 9 days (IQR
8 to 9) after cryptococcal meningitis diagnosis
Delayed ART initiation: 62 (70%) received ART within 42-day window. Median of 36
days (IQR 34 to 38) after cryptococcal meningitis diagnosis
Adherence: not reported
Outcomes Primary outcomes
• All-cause mortality. Blinded panel of 3 physicians adjudicated deaths.
• Cryptococcal meningitis relapse: defined as increasing growth of Cryptococcus on
quantitative cultures after 4 weeks of treatment
Secondary outcomes
• Time to CSF fungal clearance: was determined using “the early fungicidal activity
method. Microbiologic clearance of cryptococcus was measured by serial quantitative
cryptococcal cultures collected at screening, study entry, study day 7, any additional
therapeutic LPs, and time of outpatient clinic registration (week 4)”
• Time to death: unadjusted HR
• IRIS as defined by Haddow 2010. Blinded panel of 3 physicians adjudicated IRIS.
• Adverse events: defined according to DAIDS classification 2009
• Virological suppression: < 400 copies/mL at 26 weeks
Timing of outcome measurement: participants were followed daily while hospitalized,
then every 2 weeks for 12 weeks and monthly thereafter through 46 weeks. Lumbar
punctures were performed at diagnosis and on days 7 and 14 of amphotericin therapy
and as needed for the control of intracranial pressure
Notes Country: Uganda and South Africa
Setting: 3 hospitals
Dates: November 2010 to April 2011 (recruitment)
Funding: funded by theNational Institute of Allergy and Infectious Diseases; President’s
Emergency Plan for AIDS Relief (PEPFAR) for ART, Merck Sharp & Dohme for EFV
Others: among eligible participants with cryptococcal meningitis, 29 died after diagnosis
but before randomization. Data safety monitoring committee stopped trial early due to
excess mortality in early ART group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used a computer-generated, per-
muted-block randomization algorithm with blocks of
different sizes in a 1:1 ratio, stratified according to site
and the presence or absence of altered mental status
at the time that informed consent was obtained
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed envelopes
stored in a lockbox contained the randomization as-
signments for enrolled participants. Envelopes were
opened after written informed consent had been ob-
tained
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Boulware 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk While clinical assessors were blinded for IRIS and
mortality, assessment of adverse events was unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no cases of loss to follow-up.
Selective reporting (reporting bias) Low risk The trial authors reported all outcomes of interest and
all protocol outcomes
Other bias Low risk We did not identify any other potential sources of bias.
Makadzange 2010
Methods Study design: RCT
Participants Inclusion criteria: eligible participants were aged 18 years and HIV-positive. All par-
ticipants had cryptococcal meningitis confirmed by positive results of India ink iden-
tification of Cryptococcus neoformans in the CSF or a CSF cryptococcal polysaccharide
antigen (CrAg) test (CALAS; Meridian Diagnostics), or both. Participants residing in a
50-kilometre radius of Harare. Informed consent
Exclusion criteria: previous diagnosis of or treatment for cryptococcal meningitis, cur-
rently receiving ART, receiving medications that affect the metabolism of fluconazole
(especially rifampicin), pregnant or lactating, or a history of hepatic or renal dysfunction
Number randomized: 54
Descriptive baseline data
• Age (mean (SD) years): early ART -36.6 (±8.5); delayed ART -37.5 (±6.9)
• Sex (% male): early ART 50%; delayed ART 54%
• CD4 count (median (IQR) cells/µL): early ART 27 (17 to 69); delayed ART 51.5
(25 to 69.5)
• Fungal burden (CSF CrAg titre > 1:128 (n;%)): early ART 15 (65.2); delayed
ART 21 (87.5)
• Level of consciousness at baseline: not reported
Dropouts during study period: 8 (some numerical discrepancy in flow diagram, which
suggests 6)
Interventions Duration of antifungal therapy prior to randomization: 0 days - randomized at time
of diagnosis and treatment initiation
Antifungal therapy provided: fluconazole (800 mg once per day; Diflucan (Pfizer)),
after 10weeks reduced to a prophylactic dosage of 200mg once per day.Where treatment
failure was suspected (positive culture, positive India ink or persistently elevated CrAg
titres), dosage was increased once again to 800 mg daily until CSF clear
Supportive care: not described
CSF pressure management: CSF hypertension reduced if clinically indicated or CSF
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Makadzange 2010 (Continued)
pressure high at study visits where LPs were conducted
ART regimen: fixed-dose combination of stavudine (30 mg twice per day) and lamivu-
dine (150 mg twice per day), and nevirapine (200 mg twice per day, with a 200 mg once-
daily 2-week lead-in dose)
Early ART: started within 72 hours of randomization
Delayed ART: started after 10 weeks of antifungal therapy
Adherence: adherence to fluconazole and ART: self reports and pill counts at each visit
(not reported in outcomes)
Outcomes Primary outcomes
• All-cause mortality
Secondary outcomes
• Time to death
• Adverse events
Timing of outcome assessment: observed at outpatient clinic at 2, 4, 8, and 10 weeks,
then monthly. Liver function tests conducted 6 monthly up to 2 years. Cerebrospinal
fluid sampled at weeks 2, 4, and 10
Notes Country: Zimbabwe
Setting: a tertiary referral teaching hospital in Harare
Dates: October 2006 through April 2008
Funding: The AIDS Care Research in Africa (ACRiA) programme and the small grants
funding programme from the Infectious Diseases Society of America
Other:
• Study was terminated early by the data safety monitoring committee, and the
optimal sample size was not achieved.
• Safety concerns with regard to administration of fluconazole in high dose and
nevirapine and lack of regular LFT monitoring.
• Concerns about censoring.
• Participants were discharged from hospital within 1 week
• Numerical inconsistencies in results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomization schedule was used to as-
sign participants to the early ART and delayed ART arms of the
trial
Allocation concealment (selection bias) Low risk The randomization sequence was concealed to the trial nurse
who was responsible for participant enrolment using sealed en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
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Makadzange 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessment was not reported as blinded. Trial did not
report on IRIS. This is unlikely to bias results for mortality and
laboratory tests, however bias could be introduced for adverse
events
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up low and similar in both arms (3 out of 28
and 3/5 out of 26 in early ART and delayed ART arms)
Selective reporting (reporting bias) Unclear risk Protocol not available for review; outcomes not listed on Clin-
icalTrials.gov (protocol registered after trial was completed)
clinicaltrials.gov/ct2/show/NCT00830856
Other bias High risk Some reported results were not arithmetically correct, which
could have had an impact on effect estimates. In addition, the au-
thors were not consistent with the intention-to-treat approach,
which could have affected the time-to-event analysis. Concerns
about the results of this trial are echoed in comments from other
trial authors in the same field (Boulware 2010; Bicanic 2010;
Grant 2010).
Zolopa 2009
Methods Study design: open-label RCT
Participants Inclusion criteria: eligible participants were HIV-positive men or women 13 years
of age or older, presenting with an AIDS-defining opportunistic infection or serious
bacterial infection for which effective antimicrobial therapy was available and prescribed.
To reflect clinical practice, the trial allowed presumptive and confirmed diagnoses as
long as appropriate treatment for the opportunistic infection/bacterial infection had
been initiated (cryptococcal disease was required to be confirmed). Participants in whom
tuberculosis was diagnosed after randomization remained in the trial
Exclusion criteria: people with or on treatment for tuberculosis were excluded. People
were ineligible if they had received ART within 8 weeks prior to study entry, more than
31 days of any ART within 6 months prior to study entry, or more than 1 ART regimen
on which they experienced treatment failure
Number randomized: 35
Descriptive baseline data
• Age: not reported for cryptococcal meningitis group
• Sex: not reported for cryptococcal meningitis group
• CD4 count: not reported for cryptococcal meningitis group
• Fungal burden: not reported for cryptococcal meningitis group
• Level of consciousness at baseline: not reported for cryptococcal meningitis group
Dropouts during study period: not reported for cryptococcal meningitis group
Interventions Duration of antifungal therapy prior to randomization: <= 14 days
Antifungal therapy provided: not reported
Supportive care: not reported
CSF pressure management: not reported
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Zolopa 2009 (Continued)
ART regimen: choice of ART was left to the judgement of the clinician to better reflect
common clinical practice
Early ART: 48 hours
Delayed ART: 6 to 12 weeks
Adherence: monitored by self reporting at 8, 16, 32, and 48 weeks
Outcomes Primary outcome
• All-cause mortality
Timing of outcome assessment: participants were seen at weeks 4, 8, 12, and 16 and
every 8 weeks thereafter through week 48 for clinical assessments and routine laboratory
monitoring. Participants in the deferred arm shifted to follow-up at weeks 4, 8, 12, and
16 after initiation of ART and every 8 weeks thereafter until week 48
Notes Country: USA and South Africa
Setting: 39 AIDS Clinical Trials Units in the USA (including Puerto Rico) and Johan-
nesburg, South Africa (which was limited to enrolling 20 participants by the trial spon-
sor)
Dates: May 2003 to August 2007
Funding: AIDS Clinical Trials Group funded by the National Institute of Allergy and
Infectious Diseases
Other: how cryptococcal meningitis was confirmed was not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk After eligibility checklist was completed, randomized
treatment assignment was generated by central com-
puter using permuted blocks within strata
Allocation concealment (selection bias) Low risk Neither the size of the blocks nor treatment assign-
ments to other sites were public, which prevented in-
dividual investigators from deducing the assignment
pattern
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessment of adverse events was not blinded, which
may have introduced bias for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants lost to follow-up was not
reported exactly, however the trial authors state:
“Eighty-seven percent of subjects, 123 in each arm,
were evaluable for the primary endpoint”, suggesting
that loss to follow-up was 13% or less, which is ac-
ceptable. It is difficult to comment specifically on par-
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Zolopa 2009 (Continued)
ticipants with cryptococcal meningitis, as these results
were not disaggregated
Selective reporting (reporting bias) Unclear risk The protocol was unavailable for evaluation.
Other bias Unclear risk As the trial had so little information on the partici-
pants in our treatment group of interest, it is difficult
to comment on bias related to our trial population
Abbreviations: ART: antiretroviral therapy; CD4: cluster of differentiation 4; CFU: colony forming units; CNS: central nervous system;
CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; DAIDS: Division of AIDS; GCS: Glasgow coma score; HR: hazard ratio;
IQR: interquartile range; IRIS: immune reconstitution inflammatory syndrome; LP: lumbar puncture; RCT: randomized controlled
trial; SD: standard deviation; TDF: Tenofovir; FTC: Emtricitabine; EFV: Efavirenz; NVP: Nevirapine; AZT: Zidovudine; LFT:
Liver function test
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Makadzange 2015a Journal correspondence
Makadzange 2015b Duplicate of Makadzange 2015a
Makadzange 2015c Duplicate of Makadzange 2015a
Manosuthi 2008 Wrong study design: cohort study
Sungkanuparph 2009 Wrong study design: participants were not randomized to early or late ART. This is a substudy of a trial that
randomized participants to different cryptococcal treatment strategies
Sunpath 2012 Wrong study design: cohort study
Torok 2005 Journal correspondence
Abbreviations: ART: antiretroviral therapy
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D A T A A N D A N A L Y S E S
Comparison 1. Early versus delayed ART
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality at 6 to 12
months
4 294 Risk Ratio (M-H, Random, 95% CI) 1.42 [1.02, 1.97]
2 Sensitivity analysis: all-cause
mortality
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Cryptococcal meningitis relapse 2 205 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.07, 1.04]
4 Mortality hazard ratio 3 Hazard Ratio (Random, 95% CI) Totals not selected
5 Cryptococcal IRIS 2 205 Risk Ratio (M-H, Random, 95% CI) 3.56 [0.51, 25.02]
6 Sensitivity analysis: cryptococcal
IRIS
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Available-case analysis:
all who received ART (assume
missing completely at random)
2 178 Risk Ratio (M-H, Random, 95% CI) 2.97 [0.38, 23.25]
6.2 As randomized: intention-
to-treat analysis
2 205 Risk Ratio (M-H, Random, 95% CI) 3.56 [0.51, 25.02]
6.3 Worst-case scenario 2 205 Risk Ratio (M-H, Random, 95% CI) 3.73 [0.37, 38.07]
6.4 Best-case scenario 2 205 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.45, 5.40]
7 Virological suppression at
24 weeks (viral load < 400
copies/mL)
2 205 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.72, 1.22]
8 Sensitivity analysis: virological
suppression at 24 weeks
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Available-case analysis
(assume missing completely at
random)
2 128 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.96, 1.27]
8.2 Intention-to-treat analysis
(assume missing would not
have suppressed)
2 205 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.72, 1.22]
8.3 Best-case scenario 2 205 Risk Ratio (M-H, Random, 95% CI) 1.26 [1.10, 1.45]
8.4 Worst-case scenario 2 205 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.72, 0.96]
9 Subgrouping by antifungal drug:
all-cause mortality
4 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Ampho B + fluconazole 2 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Fluconazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Unknown antifungal drug 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Early versus delayed ART, Outcome 1 All-cause mortality at 6 to 12 months.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 1 All-cause mortality at 6 to 12 months
Study or subgroup Early ART Delayed ART Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bisson 2013 2/14 5/14 4.9 % 0.40 [ 0.09, 1.73 ]
Boulware 2014 40/88 27/89 49.9 % 1.50 [ 1.02, 2.21 ]
Makadzange 2010 22/28 13/26 43.2 % 1.57 [ 1.02, 2.42 ]
Zolopa 2009 1/13 2/22 2.0 % 0.85 [ 0.08, 8.44 ]
Total (95% CI) 143 151 100.0 % 1.42 [ 1.02, 1.97 ]
Total events: 65 (Early ART), 47 (Delayed ART)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.44, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours early ART Favours delayed ART
Analysis 1.2. Comparison 1 Early versus delayed ART, Outcome 2 Sensitivity analysis: all-cause mortality.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 2 Sensitivity analysis: all-cause mortality
Study or subgroup Early ART Delayed ART Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boulware 2014 40/88 27/89 1.50 [ 1.02, 2.21 ]
0.2 0.5 1 2 5
Delayed ART Early ART
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Analysis 1.3. Comparison 1 Early versus delayed ART, Outcome 3 Cryptococcal meningitis relapse.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 3 Cryptococcal meningitis relapse
Study or subgroup Early ART Delayed ART Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bisson 2013 0/14 1/14 15.9 % 0.33 [ 0.01, 7.55 ]
Boulware 2014 2/88 8/89 84.1 % 0.25 [ 0.06, 1.16 ]
Total (95% CI) 102 103 100.0 % 0.27 [ 0.07, 1.04 ]
Total events: 2 (Early ART), 9 (Delayed ART)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early ART Favours delayed ART
Analysis 1.4. Comparison 1 Early versus delayed ART, Outcome 4 Mortality hazard ratio.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 4 Mortality hazard ratio
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Bisson 2013 -1.3471 (0.5413) 0.26 [ 0.09, 0.75 ]
Boulware 2014 0.5481 (0.2499) 1.73 [ 1.06, 2.82 ]
Makadzange 2010 0.8502 (0.3759) 2.34 [ 1.12, 4.89 ]
0.01 0.1 1 10 100
Favours early ART Favours delayed ART
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Analysis 1.5. Comparison 1 Early versus delayed ART, Outcome 5 Cryptococcal IRIS.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 5 Cryptococcal IRIS
Study or subgroup Early ART Delayed ART Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bisson 2013 7/14 0/14 30.2 % 15.00 [ 0.94, 239.81 ]
Boulware 2014 17/88 9/89 69.8 % 1.91 [ 0.90, 4.05 ]
Total (95% CI) 102 103 100.0 % 3.56 [ 0.51, 25.02 ]
Total events: 24 (Early ART), 9 (Delayed ART)
Heterogeneity: Tau2 = 1.27; Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours early ART Favours delayed ART
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Analysis 1.6. Comparison 1 Early versus delayed ART, Outcome 6 Sensitivity analysis: cryptococcal IRIS.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 6 Sensitivity analysis: cryptococcal IRIS
Study or subgroup Early ART Delayed ART Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Available-case analysis: all who received ART (assume missing completely at random)
Bisson 2013 7/12 0/10 32.0 % 12.69 [ 0.81, 198.10 ]
Boulware 2014 17/87 9/69 68.0 % 1.50 [ 0.71, 3.15 ]
Subtotal (95% CI) 99 79 100.0 % 2.97 [ 0.38, 23.25 ]
Total events: 24 (Early ART), 9 (Delayed ART)
Heterogeneity: Tau2 = 1.48; Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.04 (P = 0.30)
2 As randomized: intention-to-treat analysis
Bisson 2013 7/14 0/14 30.2 % 15.00 [ 0.94, 239.81 ]
Boulware 2014 17/88 9/89 69.8 % 1.91 [ 0.90, 4.05 ]
Subtotal (95% CI) 102 103 100.0 % 3.56 [ 0.51, 25.02 ]
Total events: 24 (Early ART), 9 (Delayed ART)
Heterogeneity: Tau2 = 1.27; Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.28 (P = 0.20)
3 Worst-case scenario
Bisson 2013 8/14 0/14 34.9 % 17.00 [ 1.07, 268.84 ]
Boulware 2014 18/88 11/89 65.1 % 1.65 [ 0.83, 3.30 ]
Subtotal (95% CI) 102 103 100.0 % 3.73 [ 0.37, 38.07 ]
Total events: 26 (Early ART), 11 (Delayed ART)
Heterogeneity: Tau2 = 2.03; Chi2 = 2.93, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 1.11 (P = 0.27)
4 Best-case scenario
Bisson 2013 7/14 2/14 38.0 % 3.50 [ 0.88, 13.99 ]
Boulware 2014 17/88 18/89 62.0 % 0.96 [ 0.53, 1.73 ]
Subtotal (95% CI) 102 103 100.0 % 1.56 [ 0.45, 5.40 ]
Total events: 24 (Early ART), 20 (Delayed ART)
Heterogeneity: Tau2 = 0.55; Chi2 = 2.87, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.71 (P = 0.48)
0.002 0.1 1 10 500
Favours early ART Favours delayed ART
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Analysis 1.7. Comparison 1 Early versus delayed ART, Outcome 7 Virological suppression at 24 weeks (viral
load < 400 copies/mL).
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 7 Virological suppression at 24 weeks (viral load < 400 copies/mL)
Study or subgroup Early ART Delayed ART Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bisson 2013 8/14 6/14 12.4 % 1.33 [ 0.63, 2.84 ]
Boulware 2014 43/88 49/89 87.6 % 0.89 [ 0.67, 1.18 ]
Total (95% CI) 102 103 100.0 % 0.93 [ 0.72, 1.22 ]
Total events: 51 (Early ART), 55 (Delayed ART)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delayed ART Favours early ART
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Analysis 1.8. Comparison 1 Early versus delayed ART, Outcome 8 Sensitivity analysis: virological
suppression at 24 weeks.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 8 Sensitivity analysis: virological suppression at 24 weeks
Study or subgroup Early ART Delayed ART Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Available-case analysis (assume missing completely at random)
Bisson 2013 8/12 6/10 4.8 % 1.11 [ 0.58, 2.12 ]
Boulware 2014 43/47 49/59 95.2 % 1.10 [ 0.95, 1.27 ]
Subtotal (95% CI) 59 69 100.0 % 1.10 [ 0.96, 1.27 ]
Total events: 51 (Early ART), 55 (Delayed ART)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Intention-to-treat analysis (assume missing would not have suppressed)
Bisson 2013 8/14 6/14 12.4 % 1.33 [ 0.63, 2.84 ]
Boulware 2014 43/88 49/89 87.6 % 0.89 [ 0.67, 1.18 ]
Subtotal (95% CI) 102 103 100.0 % 0.93 [ 0.72, 1.22 ]
Total events: 51 (Early ART), 55 (Delayed ART)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
3 Best-case scenario
Bisson 2013 10/14 8/14 6.3 % 1.25 [ 0.71, 2.19 ]
Boulware 2014 80/88 64/89 93.7 % 1.26 [ 1.09, 1.46 ]
Subtotal (95% CI) 102 103 100.0 % 1.26 [ 1.10, 1.45 ]
Total events: 90 (Early ART), 72 (Delayed ART)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0012)
4 Worst-case scenario
Bisson 2013 9/14 10/14 7.9 % 0.90 [ 0.54, 1.50 ]
Boulware 2014 64/88 78/89 92.1 % 0.83 [ 0.71, 0.96 ]
Subtotal (95% CI) 102 103 100.0 % 0.84 [ 0.72, 0.96 ]
Total events: 73 (Early ART), 88 (Delayed ART)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
0.01 0.1 1 10 100
Favours delayed ART Favours early ART
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Analysis 1.9. Comparison 1 Early versus delayed ART, Outcome 9 Subgrouping by antifungal drug: all-cause
mortality.
Review: Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
Comparison: 1 Early versus delayed ART
Outcome: 9 Subgrouping by antifungal drug: all-cause mortality
Study or subgroup Early ART Delayed ART Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ampho B + fluconazole
Bisson 2013 2/14 5/14 0.40 [ 0.09, 1.73 ]
Boulware 2014 40/88 27/89 1.50 [ 1.02, 2.21 ]
2 Fluconazole
Makadzange 2010 22/28 13/26 1.57 [ 1.02, 2.42 ]
3 Unknown antifungal drug
Zolopa 2009 1/13 2/22 0.85 [ 0.08, 8.44 ]
0.01 0.1 1 10 100
Favours early ART Favours delayed ART
A D D I T I O N A L T A B L E S
Table 1. Cohort studies evaluating time to ART initiation in cryptococcal meningitis
Trial ID Design Location Defini-
tions
Study pe-
riod
Dura-
tion of fol-
low-up
Mortality Trial con-
clusions
Early
(n/N)
Late
(n/N)
Associa-
tion
Manosuthi
2008
Retrospec-
tive cohort
Thailand Early
< 1 month;
late ≥ 1
month
2002 to
2006
1050 pa-
tient years
9/52 46/229 Adjusted
HR 0.833
(95%CI 0.
379 to 1.
831)
No differ-
ence, how-
ever
underpow-
ered and
risks of se-
lection bias
and
unmea-
sured con-
founders
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Table 1. Cohort studies evaluating time to ART initiation in cryptococcal meningitis (Continued)
Crabtree
Ramírez
2017
Retrospec-
tive cohort
USA
and Latin
America
Early
< 2 weeks;
late 2 to 8
weeks
1985 to
2014
Unknown 7/24 14/53 Ad-
justed OR
1.09 (95%
CI 0.44 to
2.67)
No differ-
ence, how-
ever
underpow-
ered and
risks of se-
lection bias
and
unmea-
sured con-
founders
Ingle 2015 Retrospec-
tive cohort
(con-
ference ab-
stract)
North
America
Early ≤ 14
days; late
14 to 56
days since
cryptococ-
cal menin-
gitis diag-
nosis
1998 to
2009
Unknown 7/62 7/67 Crude HR
1.29 (0.
68 to 2.43)
and ad-
justed HR
1.30 (0.66
to 2.55)
No asso-
ciation be-
tween tim-
ing
and mor-
tality, how-
ever
unmea-
sured con-
founders
and selec-
tionbias an
issue
Low power
to detect a
difference
Abbreviations: ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; OR: odds ratio
Table 2. Summary of included studies
Trial ID Country Ran-
domized
(N)
Male (N;
%)
Age (me-
dian;
IQR
or mean;
SD)
Du-
ration of
antifun-
gal ther-
apy prior
to
random-
ization
Antifun-
gal regi-
men
Time to ART initi-
ation after random-
ization
ART reg-
imen1
Drop-
outs (N)
Early Delayed
Bisson
2013
Botswana 28 14; 50 35 (32 to
41)
72 hrs Ampho-
tericin
B and flu-
conazole
7 days
(range 5
to 10)
32 days
(range 28
to 36)
TDF/
FTC/
EFV or
NVP
1
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Table 2. Summary of included studies (Continued)
Boulware
2014
Uganda,
South
Africa
177 93; 53 35 (28 to
40) early;
36 (30 to
40)
delayed
7 to 11
days
Ampho-
tericin
B and flu-
conazole
1 to 2
weeks af-
ter diag-
nosis
5
weeks af-
ter diag-
nosis
AZT/
3TC/
EFV
(80%),
D4T/
3TC/
EFV
(19%),
TDF/
3TC/
EFV
(1%)
0
Makadzange
2010
Zim-
babwe
54 28; 52 37 (SD 8.
5) early;
38 (SD 6.
9)
delayed
0 days Flucona-
zole
72 hours 10 weeks D4T/
3TC/
NVP
6
Zolopa
20092
USA,
Puerto
Rico,
South
Africa
35 NR NR ≤ 14 days NR 48 hours 6 to 12
weeks
NNRTI
or PI +
2 NRTIs
(3TC or
FTC)
NR
Abbreviations: IQR: interquartile range; N: number of participants; NR: not reported; SD: standard deviation; AZT: Zidovudine;
D4T: Stavudine
1TDF: tenofovir; FTC: emtricitabine; EFV: efavirenz;NVP: nevirapine; 3TC: lamivudine;NNRTI: non-nucleoside reverse transcriptase
inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
2This trial reported results for participants with a variety of opportunistic infections and did not provide descriptive data specifically
for those with cryptococcal meningitis.
Table 3. Cerebrospinal fluid fungal clearance results
Trial ID Number of participants
assessed for this outcome
Trial conclusions Results
Early ART Delayed ART
Bisson 20131 28 No difference between
groups
Rate of fungal clearance: -
0.32 log10 CFUs/mL/day
Rate of fungal clearance: -
0.52 log10 CFUs/mL/day
Boulware 20142 166 No difference between
groups
CSF culture positivity at
14 days of amphotericin
B therapy: cumulative in-
cidence of 37% (95% CI
26% to 49%)
CSF culture positivity at
14 days of amphotericin
B therapy: cumulative in-
cidence of 39% (95% CI
28% to 50%)
Abbreviations: CFU: colony forming units; CI: confidence interval; CSF: cerebrospinal fluid
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1The trial authors reported: “The median numbers of CSF CFU measurements for the control and intervention arms, respectively,
were 3 (IQR, 2-4 [range, 1-9]) and 4 (IQR, 2-5 [range, 1-7]) (P = .2, rank-sum test). The generalized estimating equation regression
coefficient for the intervention was 0.20 (95% CI, -.85 to 1.25), indicating that intervention subjects had a rate of CSF clearance that
tended to be 0.20 log10 CSF CFU/mL/day slower than controls, although this difference was not significant.”
2The trial authors reported: “Similar rates of CSF culture positivity at 14 days (37% in the earlier-ART group and 39% in the deferred-
ART group, P = 0.87). Among 59 participants with positive CSF cultures at 14 days, the median cryptococcal growth was 100 CFU
per millilitre (interquartile range, 15 to 500), with no significant difference between treatment groups (P = 0.13); only 5 participants
had more than 10,000 CFU per millilitre in CSF.”
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Search Query
8 Search (((#5 AND #6))) AND (“1980/01/01”[Date - Publication] : “2017/08/07”[Date - Publication])
7 Search (#5 AND #6)
6 Search (time[tiab] OR timing[tiab] OR early[tiab] OR earlier[tiab] OR delay*[tiab] OR defer*[tiab] OR late[tiab]) AND
(initiat*[tiab] OR administrat*[tiab] OR treatment[tiab] OR therapy[tiab] OR ART[tiab] OR antiretroviral*[tiab]))
5 Search (#1 AND #2 AND #3 AND #4)
4 Search (randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR drug
therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
3 Search (“Meningitis, Cryptococcal”[Mesh] OR cryptococcal meningitis[tiab] OR cryptococal meningitis[tiab] OR cryp-
tococcal meningitides[tiab] OR cerebral cryptococcosis[tiab] OR cerebral cryptococcoses[tiab] OR toruloma*[tiab] OR
cryptococcus neoforman[mh] OR cryptococcus neoforman[tiab] OR ((cryptococcal[tiab] OR cryptococal[tiab] OR cyp-
tococcosis[tiab] OR cryptococcoses[tiab] OR Cryptococcus[tiab]) AND (meningitis[tiab]))
2 Search (antiretroviral therapy, highly active[MeSH] OR anti-retroviral agents[MeSH] OR antiviral agents[MeSH:NoExp]
OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti[tiab]) AND (retroviral*[tiab])) OR HAART[tiab]
OR ((anti[tiab]) AND (acquired immunodeficiency[tiab])) OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immune-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (defi-
ciency[tiab]))
1 Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR
hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR
human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (defi-
ciency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR ac-
quired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab])
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AND (deficiency syndrome[tiab]))
Appendix 2. Embase search strategy
Search Query
13 #10 AND #11 AND [1980-2017]/py
12 #10 AND #11
11 (time:ab,ti OR timing:ab,ti OR early:ab,ti OR earlier:ab,ti
OR delay*:ab,ti OR defer:ab,ti OR late:ab,ti) AND (initiat*:
ab,ti OR administrat*:ab,ti OR treatment:ab,ti OR therapy:
ab,ti OR art:ab,ti OR antiretroviral*:ab,ti)
10 #1 AND #2 AND #8 AND #9
9 ’cryptococcal meningitis’/de OR ’cryptococcal meningitis’:
ab,ti OR ’cryptococcus meningitis’:ab,ti OR ’cryptococal
meningitis’:ab,ti OR ’cryptococcal meningitides’:ab,ti OR
’cerebral cryptococcosis’:ab,ti OR ’cerebral cryptococcoses’:
ab,ti OR toruloma*:ab,ti OR ’cryptococcus neoforman’:ab,
ti OR ((cryptococcal:ab,ti OR cryptococal:ab,ti OR crypto-
coccosis:ab,ti OR cryptococcoses:ab,ti) AND meningitis:ab,
ti)
8 #3 NOT #7
7 #4 NOT #6
6 #4 AND #5
5 ’human’/de OR ’normal human’/de OR ’human cell’/de
4 ’animal’/de OR ’animal experiment’/deOR ’invertebrate’/de
OR ’animal tissue’/de OR ’animal cell’/de OR ’nonhuman’/
de
3 ’randomized controlled trial’/de OR ’randomized controlled
trial’ OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR fac-
torial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volun-
teer*:ab,ti OR ’crossover procedure’/de OR ’crossover pro-
cedure’ OR ’double-blind procedure’/de OR ’double-blind
procedure’ OR ’single-blind procedure’/de OR ’single-blind
procedure’ OR ((doubl* NEAR/3 blind*):ab,ti) OR (singl*:
ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:
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ab,ti OR ((cross NEXT/1 over*):ab,ti)
2 ’human immunodeficiency virus vaccine’/exp OR ’human
immunodeficiency virus vaccine’ OR ’human immunod-
eficiency virus vaccine’:ab,ti OR ’anti human immuned-
eficiency’:ab,ti OR ’anti human immunodeficiency’:ab,ti
OR ’anti human immuno-deficiency’:ab,ti OR ’anti human
immune-deficiency’:ab,ti OR ’anti acquired immune-defi-
ciency’:ab,ti OR ’anti acquired immunedeficiency’:ab,ti OR
’anti acquired immunodeficiency’:ab,tiOR ’anti acquired im-
muno-deficiency’:ab,ti OR ’anti hiv’:ab,ti OR antiretrovir*:
ab,ti OR ’anti retroviral’:ab,ti OR ’anti retrovirals’:ab,ti OR
’anti retrovirus’:ab,ti OR haart:ab,ti OR ’aids vaccine’:ab,ti
OR ’aids vaccines’:ab,ti OR ’anti human immunodeficiency
virus agent’/exp OR ’anti human immunodeficiency virus
agent’ OR ’anti human immunodeficiency virus agent’:ab,
ti OR ’antiretrovirus agent’/exp OR ’antiretrovirus agent’
OR ’antiretrovirus agent’:ab,ti OR ’highly active antiretrovi-
ral therapy’/expOR ’highly active antiretroviral therapy’ OR
’highly active antiretroviral therapy’:ab,ti
1 ’human immunodeficiency virus infection’/exp OR ’hu-
man immunodeficiency virus infection’ OR ’human im-
munodeficiency virus’/exp OR ’human immunodeficiency
virus’ OR ’human immunodeficiency virus’:ab,ti OR ’hu-
man immuno+deficiency virus’:ab,ti OR ’human immuned-
eficiency virus’:ab,ti OR ’human immune+deficiency virus’:
ab,ti OR hiv:ab,ti OR ’hiv-1’:ab,ti OR ’hiv-2’:ab,ti OR ’ac-
quired immunodeficiency syndrome’:ab,ti OR ’acquired im-
muno+deficiency syndrome’:ab,ti OR ’acquired immuned-
eficiency syndrome’:ab,ti OR ’acquired immune+deficiency
syndrome’:ab,ti
WH A T ’ S N E W
Last assessed as up-to-date: 7 August 2017.
Date Event Description
23 July 2018 New search has been performed This is an update of a review last published in 2013 (Njei
2013). The review author team updated the protocol ex-
tensively, and differences are highlighted in the ‘Differences
between protocol and review’ section.
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23 July 2018 New citation required and conclusions have changed The previous Cochrane Review conducted by Njei 2013
concluded that there was insufficient evidence to determine
whether early ART had an effect on mortality and suggested
that there was a higher risk of IRIS among those who initiated
ART early. This review update did show some evidence of
higher risk of IRIS in the early ART group, but the certainty
of the evidence contributing to this outcome was very low.
The additional trials that contributed to this updated review,
and rigorous application of theGRADE tool, resulted in low-
certainty evidence of higher mortality among those who ini-
tiated ART early
C O N T R I B U T I O N S O F A U T H O R S
Mbah P Okwen, Tihana Bicanic, Marty Richardson, and Ingrid Eshun-Wilson developed the protocol. Mbah P Okwen and Ingrid
Eshun-Wilson screened and appraised studies, consulting either Tihana Bicanic or Marty Richardson in case of disagreement. Marty
Richardson provided expert contributions on statistics, and Tihana Bicanic provided expert inputs on cryptococcal meningitis content.
Ingrid Eshun-Wilson andMarty Richardson conducted the analyses. Ingrid Eshun-Wilson andMbah POkwen drafted the final review,
which the remaining author team reviewed.
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External sources
• Department for International Development, UK.
Grant: 5242
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of a previous Cochrane review (Njei 2013). The new review author team extensively revised the protocol, which is
available on the CIDG website at cidg.cochrane.org/our-reviews under the subheading ‘Related content’.
I N D E X T E R M S
Medical Subject Headings (MeSH)
AIDS-Related Opportunistic Infections [drug therapy]; Anti-HIV Agents [∗administration & dosage]; Antifungal Agents
[∗administration & dosage]; Drug Administration Schedule; HIV Infections [complications; ∗drug therapy]; Meningitis, Cryptococcal
[complications; ∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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